Etude : 2017-01 /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Type d'étude
MÀJ
Présentation de l'étude
Acronyme : 2017-01

Nom :

Traitement :

Type d'étude : Qualité de vie / Observationnelle

Dernière MÀJ : 17/07/2019
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Spécialité : Organes digestifs
Localisation : C22 - Tumeur maligne du foie et des voies biliaires intrahépatiques
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : Subjects with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing HCC surveillance will be enrolled and have blood samples collected. Subjects undergoing HCC surveillance will be followed for 6 months and another blood sample collected at the 6 month time point.

Phase : NA

Stade : I à IV

1
Critères d'inclusion
Critères de non-inclusion
Critères d'inclusion et de non-inclusion
Critères d'inclusion : All Subjects:
1- Subject is 18 years of age or older
2- Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of data, including personal health data, to the study investigator and sponsor

HCC Subjects:
1- Subject has a recent (within 6 months of enrollment) untreated clinically diagnosed hepatocellular carcinoma as defined by ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and/or capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC.

Control Subjects:
1- Non-cancer subject undergoing routine imaging surveillance for HCC
2- Definitive lack of HCC within 3 months prior to enrollment as defined by negative imaging, for HCC.
- Control Group 1 - negative by ultrasound
- Control Group 2 - negative by CT or MRI

Critères de non-inclusion : 1- Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).
2- Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
3- Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.
4- Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).
5- IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.
6- Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
7- Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
8- Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
Promoteur :
Exact Sciences Corporation
Type de sponsor : Industriel
-
00000 HORS FRANCE

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Hospitalier Universitaire de Lille - 2 Avenue Oscar Lambret - 59000 LILLE

Investigateur :
Professeur Philippe MATHURIN

TEC / ARC / IDE :
Madame Daphnée SORET
Daphnee.SORET@
CHRU-LILLE.FR
03 20 44 59 62 - Poste 30671

Ouverture de l'essai : CLOS

MAJ : 17/07/2019